Alzheimer's disease (AD) stands as the predominant form of dementia, presenting significant
and escalating global challenges. Its etiology is intricate and diverse, stemming from a …

Recent Aβ-immunotherapy trials have yielded the first clear evidence that removing
aggregated Aβ from the brains of symptomatic patients can slow the progression of …

Proteomic studies of human Alzheimer's disease brain tissue have potential to identify
protein changes that drive disease, and to identify new drug targets. Here, we analyse 38 …

Human studies consistently identify bioenergetic maladaptations in brains upon aging and
neurodegenerative disorders of aging (NDAs), such as Alzheimer's disease, Parkinson's …

The abnormal amyloid‐β accumulation is essential and obbligato in Alzheimer's disease
pathogenesis and natural polyphenols exhibit great potential as amyloid aggregation …

Alzheimer's disease (AD) is a multifaceted, advancing neurodegenerative illness that is
responsible for most cases of neurological impairment and dementia in the aged population …

The dominant risk factors for late-onset Alzheimer's disease (AD) are advanced age and the
APOE4 genetic variant. To examine how these factors alter neuroimmune function, we …

Dendrite pathology and synaptic loss result in neural circuit dysfunction, a common feature
of neurodegenerative diseases. There is a lack of strategies that target dendritic and …

Alzheimer's disease (AD) is the most common neurodegenerative disorder, characterized
pathologically by extracellular deposition of β-amyloid (Aβ) into senile plaques and …

Proteins work together in nanostructures in many physiological contexts and disease states.
We recently developed expansion revealing (ExR), which expands proteins away from each …